Seres Therapeutics, Inc. (MCRB) trades at a trailing P/E of 13.3. Trailing earnings yield is 7.49%. Graham Number is $8.50.
Criteria proven by this page:
Overall SharesGrow Score: 56/100 with 2/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -4.3 | 3.35 | 2.97 | 18.12 | - |
| 2017 | -4.6 | 1.17 | 6.76 | 12.78 | - |
| 2018 | -1.9 | -0.19 | -3.83 | 6.52 | - |
| 2019 | -2.8 | 0.06 | -4.04 | 5.66 | - |
| 2020 | -21.9 | 2.20 | 11.19 | 58.85 | - |
| 2021 | -11.6 | 0.32 | 5.81 | 5.27 | - |
| 2022 | -2.4 | -0.01 | 56.13 | 0.00 | - |
| 2023 | -1.6 | 0.03 | -4.00 | 0.00 | - |
| 2024 | 949.5 | 154.80 | 9.37 | 0.00 | - |
| 2025 | 23.1 | -0.22 | 2.98 | 167.07 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-2.30 | $21.77M | $-91.58M | -420.7% |
| 2017 | $-2.21 | $32.1M | $-89.38M | -278.4% |
| 2018 | $-2.43 | $28.27M | $-98.94M | -350% |
| 2019 | $-1.13 | $34.51M | $-64.24M | -186.2% |
| 2020 | $-1.08 | $33.22M | $-86.45M | -260.3% |
| 2021 | $-0.67 | $144.93M | $-61.5M | -42.4% |
| 2022 | $-2.35 | $7.13M | $-253.82M | -3560.9% |
| 2023 | $-0.89 | $126.33M | $-113.72M | -90% |
| 2024 | $0.00 | $0.00 | $136K | - |
| 2025 | $0.64 | $789K | $5.7M | 721.9% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-8.23 | $-8.23 – $-8.23 | $25M | $25M – $25M | 1 |
| 2027 | $-9.17 | $-9.17 – $-9.17 | $41.67M | $41.67M – $41.67M | 1 |
| 2028 | $-10.23 | $-10.23 – $-10.23 | $296.16M | $296.16M – $296.16M | 1 |
| 2029 | $-8.80 | $-8.80 – $-8.80 | $249.64K | $249.64K – $249.64K | 1 |
